Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Prone Positioning and Thoracoabdominal Binding on Lung and Muscle Protection in ARDS Patients During Spontaneous Breathing

23 de septiembre de 2026 actualizado por: Rodrigo Cornejo, University of Chile

Effect of Prone Positioning and Thoracoabdominal Binding on Lung and Muscle Protection in ARDS Patients With ICU-acquired Weakness Transitioning From Controlled to Spontaneous Breathing

Ventilator-induced diaphragmatic dysfunction and intensive care unit (ICU)-acquired weakness are two consequences of prolonged mechanical ventilation and critical illness in patients with acute respiratory distress syndrome (ARDS). Both complicate the process of withdrawing mechanical ventilation, increase hospital mortality and cause chronic disability in survivors. During transition from controlled to spontaneous breathing, these complications of critical illness favor an abnormal respiratory pattern and recruit accessory respiratory muscles which may promote additional lung and muscle injury. The type of ventilatory support and positioning may affect the muscle dysfunction and patient-self-inflicted lung injury at spontaneous breathing onset. In that regard, ARDS patients with ventilator-induced diaphragmatic dysfunction and ICU-acquired weakness who are transitioning from controlled to partial ventilatory support probably present an abnormal respiratory pattern which exacerbates lung and muscle injury. Physiological-oriented ventilatory approaches based on prone positioning or semi recumbent positioning with abdominal binding at spontaneous breathing onset, could decrease lung and muscle injury by favoring a better neuromuscular efficiency, and preventing intense inspiratory efforts and high transpulmonary driving pressures, as well as high-magnitude pendelluft. In the current project, in addition to perform a multimodal description of the severity of ventilator-induced diaphragmatic dysfunction and ICU-acquired weakness in prolonged mechanically ventilated ARDS patients, prone positioning and supine plus thoracoabdominal binding at spontaneous breathing onset will be evaluated.

Descripción general del estudio

Descripción detallada

The study was designed in three phases: a multimodal physiological description, a randomized crossover trial, and a pilot randomized trial. The multimodal physiological description and the randomized crossover trial were conducted in the same cohort. The pilot randomized trial was not conducted.

Multimodal Physiological Description Phase: a multimodal physiological description was performed to characterize ICU acquired weakness and ventilator-induced diaphragm dysfunction in prolonged mechanically ventilated ARDS patients at spontaneous breathing onset, in pressure support ventilation mode. The assessments included conventional electromyography (cEMG); electrical activity of the diaphragm; respiratory muscle ultrasound; respiratory flow; tidal volume; airway, esophageal and gastric pressures; and hemodynamic and electrical impedance tomography monitoring. Diaphragm ultrasound and cEMG were performed after the crossover trial, to avoid reducing PEEP and PS to the standardized low values required for diaphragm ultrasound (PEEP and PS of 6 cmH2O) before the crossover conditions, which could alter respiratory mechanics at protocol entry; cEMG findings were not expected to change over this timeframe (amendment approved by IRB No. 45/2024; May 15, 2024).

Randomized Crossover Trial Phase: Patients were asigened in random order to three 60-minute conditions on pressure support ventilation mode: A.- Control group: semi-recumbent position at 45º (previously described as supine at 45º), B.- Thoracoabdominal binding: semi-recumbent position at 45º plus thoracoabdominal binding, C.- Prone positioning (without thoracoabdominal binding). These strategies were performed under individualized PEEP (obtained at the lowest combination of collapse and overdistension according to electrical impedance tomography), with 15-minute washout periods of in assisted/controlled ventilation between conditions.

Pilot Randomized Trial Phase: This phase was designed to randomize patients to one of the three strategies under standard PEEP (ARDSNet strategy), with PET/CT imaging and biomarker analysis. The originally registered enrollment (n = 36) corresponded to this phase. A protocol amendment approved by the local ethics committee in May 2024 established that patients enrolled in this phase were not required to have completed the multimodal description and crossover phases, and reduced the planned sample size to 12 patients due to budgetary and logistical constraints. The phase was ultimately not conducted; the decision not to conduct it was reported to the local ethics committee and approved by the national funding agency.

Enrollment: The target enrollment for the crossover phase (24 patients) was established in the May 2024 protocol amendment. Recruitment was closed after 14 patients had been enrolled.

Tipo de estudio

Intervencionista

Inscripción (Actual)

14

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Independencia, Chile
        • Hospital Clínico Universidad de Chile

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Adult ARDS patients with moderate-severe ARDS on controlled protective mechanical ventilation for more than 2 days (modified from "more than 3 days" by the protocol amendment approved in May 2024)
  • Stable hemodynamics
  • Level of consciousness enough to initiate spontaneous breathing

Exclusion Criteria:

  • Unstable hemodynamics
  • Tracheostomy
  • Abnormal level of consciousness
  • Central nervous system injury
  • Esophageal varices
  • Pregnancy
  • Contraindications for installation of electrical impedance tomography or nasogastric catheter placement
  • Contraindications for prone positioning and thoracoabdominal binding
  • Chronic neuromuscular disorders
  • Obstructive lung disease; intrinsic positive end-expiratory pressure (PEEP) ≥3 cmH₂O (measured without inspiratory effort);
  • Recent-onset sepsis and moderate-to-severe metabolic acidosis;
  • Multi-organ failure with high short-term mortality risk
  • Clinical evidence of respiratory or hemodynamic instability

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Cuidados de apoyo
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Control Group

ARDS patients at spontaneous breathing onset on pressure support ventilation mode in semi-recumbent position at 45º degrees, performed under individualized PEEP applied in random order.

ARDS patients at spontaneous breathing onset on pressure support ventilation mode in supine position at 45º degrees, performed under standard PEEP according to ARDSNet strategy and individualized PEEP applied in random order.

Experimental: Prone Positioning

ARDS patients at spontaneous breathing onset on pressure support ventilation mode in prone position, performed under individualized PEEP applied in random order.

Prone positioning will be performed according to ICU local protocol with trained provider teams.

Experimental: Thoracoabdominal Binding

ARDS patients at spontaneous breathing onset on pressure support ventilation mode in semi-recumbent position at 45º degrees using thoracoabdominal binding with the binder's upper edge above the costal margin, performed under individualized PEEP applied in random order.

Thoracoabdominal binding will be used in semi-recumbent position (at 45º) and titrated to obtain a approximately 20% decrease in chest wall compliance and 1-3 cm H2O increase in end-expiratory gastric pressure during steady-state breathing

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
(Randomized Crossover Trial Phase) Pendelluft Magnitude
Periodo de tiempo: One hour on each ventilatory strategy

Pendelluft magnitude monitored by electrical impedance tomography, analyzed as a continuous variable. Title corrected in September 2026 from "High-Magnitude Pendelluft", as no threshold was prespecified and the sample size calculation was based on a continuous outcome, according to the protocol amendment approved in May 2024.

One hour on each ventilatory strategy
(Randomized Crossover Trial Phase) Neuromechanical Coupling of the Diaphragm
Periodo de tiempo: One hour on each ventilatory strategy

Ratio between transdiaphragmatic pressure and electrical activity of the diaphragm, measured by an esophageal/gastric catheter. Co-primary outcome with pendelluft magnitude. Prespecified as primary in the ethics-approved protocol and described in the Brief Summary and as a secondary outcome of the Pilot Randomized Trial Phase, but omitted in error from the Crossover Phase outcomes in the original registration. Added in September 2026.

One hour on each ventilatory strategy

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
(Randomized Crossover Trial Phase) Respiratory Mechanics Variables
Periodo de tiempo: One hour on each ventilatory strategy

Esophageal pressure swing, gastric pressure, transdiaphragmatic pressure and transpulmonary driving pressure measured by a esophageal/gastric catheter

One hour on each ventilatory strategy

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Rodrigo Cornejo, University of Chile

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

6 de diciembre de 2023

Finalización primaria (Actual)

28 de agosto de 2025

Finalización del estudio (Actual)

28 de agosto de 2025

Fechas de registro del estudio

Enviado por primera vez

6 de marzo de 2023

Primero enviado que cumplió con los criterios de control de calidad

21 de abril de 2023

Publicado por primera vez (Actual)

24 de abril de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

28 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

23 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

De-identified individual participant data underlying the published results will be available upon reasonable request to the principal investigator, subject to approval by the local ethics committee and a data use agreement.

Marco de tiempo para compartir IPD

Beginning after publication, for 5 years.

Criterios de acceso compartido de IPD

Researchers with a methodologically sound proposal, after ethics committee approval.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir